What is Rua Bioscience?
Rua Bioscience, established in 2016 as a subsidiary of Hikurangi Enterprises Ltd, is a New Zealand-based medicinal cannabis company focused on plant breeding and genetics. The company is recognized as a global innovator, with its expert team specializing in the cultivation and processing of cannabinoid-based plants for clinically proven medicines. Operating with a mission to 'heal the people and heal the land,' Rua Bioscience aims to advance the global understanding of medicinal cannabis products, emphasizing quality, sustainability, and innovation. It holds the distinction of being the first company in New Zealand to receive a license for cultivating pharmaceutical-grade cannabis and the first to legally import high THC seeds.
How much funding has Rua Bioscience raised?
Rua Bioscience has raised a total of $1.2M across 1 funding round:
Other Financing Round
$1.2M
Other Financing Round (2025): $1.2M, investors not publicly disclosed
What's next for Rua Bioscience?
The recent major strategic investment positions Rua Bioscience for accelerated growth and further development in the burgeoning medicinal cannabis market. This capital infusion is expected to bolster its research and development initiatives, expand its cultivation and processing capabilities, and potentially facilitate market penetration into new territories. The company's focus on plant breeding and genetics, coupled with its early mover advantage in New Zealand's regulatory landscape, suggests a strategic trajectory aimed at solidifying its leadership in providing high-quality, sustainable cannabis-based medicines.
See full Rua Bioscience company page
